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Abstract: Aim: Stages I and II malignant pleural mesothelioma (MPM) can be satisfactorily treated with extended 
extrapleural pneumonectomy (EPP). We modified our diagnostic methods and surgical techniques to improve outcome. 
Methods: 74 patients were treated with EPP, 33 from 1988 to May 2000 (first group), and 41 from June 2000 to 2010 
(second group) and all underwent thoracoscopy without mediastinoscopy or laparoscopy prior to EPP. We began to make 
changes in surgical management in group 2 (2000-2010). Staging was improved using 3D CT scan and Standard Uptake 
Values (SUV) provided by 2-[Fluorine-18]fluro-2-deoxy-D-glucose positron emission tomography (FDG PET) scan. Talc 
pleurodesis was used preoperatively in 15 cases. Double unilateral thoracotomy, performed on 24 patients, facilitated 
dissection of the diaphragm and made alterations in the reconstructive phase possible. Polytetrafluoroethylene (PTFE) 
prostheses were used instead of biological materials. In 10 cases the pericardium was not reconstructed on the left side 
after the previous negative experience of functional pericardial concretio that needed the prosthesis removal (Table 1). 
Topical thrombin was used to reduce postoperative complications whereas posterior prosthetic packing was used to 
prevent paraprosthetic evisceration and reduce postoperative bleeding. 
Results: Patients of group 2 experienced less morbidity. Fourteen of the 71 patients who survived beyond the immediate 
postoperative period lived at least 3 years. Potential positive prognostic factors were identified at follow-up. 
Conclusions: The innovations we adopted, especially the reconstruction procedures, improved the outcome for our series 
of patients who underwent extended EPP for MPM. Follow-up results suggest that the MIB-1 index, stage 1 disease, 
prosthetic diaphragmatic replacement, adjuvant radiotherapy and control are important positive prognostic factors. 
Keywords: Double thoracotomy, extrapleural pneumonectomy, malignant pleural mesothelioma, PET staging, reconstruction 
procedures, adjuvant tomotherapy. 
INTRODUCTION 
 Over the past 10 years, it has been shown that 
extrapleural pneumonectomy extended to the pericardium 
and diaphragm (EPP) can achieve satisfactory results in the 
treatment of stage I-II malignant pleural epithelial 
mesothelioma (MPM), especially as part of trimodality 
therapy [1,2]. Neoadjuvant pemetrexed (Eli Lilly and 
Company, Indianapolis, IN) plus cisplatin (Cadila 
Pharmaceuticals Ltd., Ahmedabad, India) chemotherapy 
followed by EPP and radiotherapy [3], surgery combined 
with intraoperative hyperthermic chemotherapy [4], 
photodynamic therapy [5], and immunotherapy [6] have all 
been found to have limited long term efficacy. Based on 
these data and the results we achieved from the first part of 
our case series (1988-2000), using surgery plus adjuvant  
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Table 1. Case Series Divided into 2 Groups with the Relative 
Morbidity and Mortality 
 
Major Surgical Morbidity? 01/1988-05/2000?
33 cases (27,2%)?
05/2000-07/2010?
41 cases (14,6%)?
Consumation coagulopathy? 3? 2?
Hemorrhage? 1 (+)? ?
Paraprosthetic evisceration? 2? ?
Concretio pericardii? 1? 1?
Thoracotomy dehiscence? 1? ?
ARDS? ? 1 (+)?
IMA? ? 1 (+)?
Pleural empyema? 1? 1?
Perioperative Mortality? 3%? 4,9%?
+Cause of death. 
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radiotherapy [7] and by other [8] studies, we gradually 
modified our clinical approach. We have made technical 
innovations to correct any possible errors (such as the use of 
posterior packing to prevent paraprosthetic evisceration and 
avoiding the placement of pericardial prosthesis on the left 
side) and to move beyond previous limitations while 
continuing to use EPP plus adjuvant radiotherapy and 
chemotherapy whenever possible. 
PATIENTS AND METHODS 
 Clinical data from 1988-2010 are presented on the radical 
treatment with EPP of 74 patients (63 men and 11 women; 
aged 29-74 years), suffering from preoperative stage I and 
stage II MPM. There were 67 cases of epithelial MPM and 7 
cases of biphasic MPM. 
 Histology was always carried out using a thoracoscopic 
biopsy from a port, except for two patients in the first group 
(1988-2000) and two in the second group (2001-2010), in 
whom a diagnostic sample could be obtained only after 
extrapleural dissection during thoracotomy. Nonetheless, ten 
biopsies on various pleural specimens through one access 
point, to avoid parietal diffusion of tumor cells, were 
performed in these four patients who were not diagnosed 
preoperatively. All four of these patients were stage I. 
Staging was performed up until 2005 through pleuroscopy, 
CT and MRI in order to evaluate costal, pericardium and 
diaphragmatic limits without having to carry out 
mediastinoscopy and laparoscopy to establish stage III in the 
absence of suspicious or confirmatory radiological elements. 
Starting in 2007, FDG PET scan, together with three-
dimensional (3D) CT, were used to establish stage II. In two 
patient’s thoracoscopic biopsy was performed after 
pulmonary collapse using a Carlens tube under general 
anesthesia due to lack of pleural fluid. 
 Group 1 consisted of 33 patients who underwent radical 
en bloc EPP via extrapleural separation of the cupola, with 
pericardial exeresis, intrapericardial vascular suturing, 
manual suturing of the bronchi at their origin, and, in most 
cases, subtotal exeresis of the right hemidiaphragm followed 
by autologous reconstruction. 
 Group 2 consisted of 41 patients and is characterized by 
innovations we made in diagnostic procedures and surgical 
techniques. 
 The criteria of cardiorespiratory function in patients 
undergoing surgery were based on a predicted ideal forced 
expiratory volume (FEV1) > 1.3 L and an ejection fraction 
>45% on cardiac ultrasound. Increasing importance was 
given to the diffusion level of carbon dioxide (DLCO) in 
patients with bronchial obstruction and to echocardiography 
results in patients with coronary artery disease. Imaging used 
for staging was improved in the last 19 cases, through use of 
3D CT scan of the pericardium, border of the aorta, 
diaphragm, and chest wall (Fig. 1). This technique was also 
used in restaging. 
 In the last 16 cases another contribution to clinical 
imaging, was made with FDG PET scan which defined 
tumor aggressivity by means of standard uptake value 
(SUV), calculated according to standard methods based on 
the uptake of FDG in grams per millimeter corrected for the 
injected FDG dose and adjusted for the patient’s weight, in 
relation to hyperfixation in areas of pathological metabolic 
activity and grading. SUV was also used to evaluate 
mediastinal, cervical, and retroperitoneal lymph nodes, and 
the retroperitoneum and diaphragm (Fig. 2). 
 
Fig. (1). 3D-CT scan of the chest showing the borders of the 
mediastinum, diaphragm, pleura, pericardium, aorta and chest wall. 
 
Fig. (2). FDG PET scan of a patient with stage I epithelial MPM 
showing the involvement of the mediastinal posterior and right 
parietal pleura. 
 The preoperative, resective and reconstructive phases of 
treatment changed significantly. In the last 16 cases 
preoperative talc pleurodesis was performed. Two to three 
weeks before surgery, talc was administered through a chest 
tube or during pleuroscopy, to patients examined in other 
institutions. Twenty-four of the 41 patients in group 2, 
underwent a double unilateral thoracotomy, the last 16 
consecutively : first a classic thoracotomy by posterolateral 
incision along the 6
th
 rib, and then a thoracotomy by 
posterior incision along the 11
th
 rib. This technique greatly 
facilitated the dissection of the diaphragmatic insertions 
without causing functional or organic damage. The last ten 
left EPP procedures were performed without reconstruction 
of the pericardium, leaving the heart free in the chest cavity, 
since double unilateral thoracotomy permitted more caudal 
anchoring of the diaphragmatic prosthesis, resulting in better 
positioning of the heart. In right EPP procedures a 0.1 mm 
thick PFTE pericardial prosthesis was always applied, 
anchored to the posterior, paraesophageal, and anterior 
retrosternal remnants of the pericardium, leaving the cranial 
and caudal parts of the pericardial sac free. The homolateral 
diaphragm was removed in all 41 patients and replaced by a 
2mm thick 20x30 cm PFTE prosthesis, the most recent 
version of which has a corrugated antibacterial surface (W. 
L. Gore, Flagstaff, AZ). All diaphragmatic prostheses benefit 
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from a more solid anchorage with interrupted sutures in a U 
shape at the level of the 10
th
 rib and the base of the 
pericardium. 
RESULTS 
 Three (4.3%) of the 74 patients (63 men and 11 women) 
who underwent EPP died in the early postoperative phase. 
One died of hemorrhagic shock caused by dehiscence of the 
sutures on the left subclavian artery at its origin on 
postoperative day 1, the second of massive myocardial 
infarction on day 2, and the third of left-sided acute 
respiratory distress syndrome (ARDS), possibly due to 
pulmonary microemboli identified by angio CT scan and 
echocardiography, 40 days after surgery. The average 
mortality rate (excluding the above 3 cases) was 4.2%; 1 
patient out of 33 (3%) in the first part of the series and 2 out 
of 41 (4.9%) in the second part. Surgical morbidity was 
greater in the first 33 patients (27.2%) than in the other 41 
(14.6%). This overall improvement permitted us to 
administer adjuvant therapy according to Sugarbaker’s 
criteria [8] in a higher number of operated patients. 
 Major surgical complications included posterior 
paraprosthetic evisceration into the left hemithorax in 2 cases 
(in the first group), hemothorax from consumption 
coagulopathy in 5 cases (3 in the first group, 2 in the second 
group), pleural empyema in 2 cases (1 in each group), and 
thoracotomy dehiscence in 1 case (first group). 
 A frequent complication is bleeding, which has been 
reduced by the use of topical thrombin, (FloSeal; Baxter Inc, 
Deerfield, IL), a novel matrix hemostatic sealant composed 
of collagen-derived particles and topical bovine-derived 
thrombin applied to all bleeding areas of the chest wall. 
Thrombin cannot be used in patients who are allergic to 
materials of bovine origin and is ineffective in patients who 
suffer from coagulation defects. Bleeding was dramatically 
reduced in the second group of patients: average blood loss 
during the first 24 hours after surgery was 900-1400 ml in 
group 1 patients, but only 300-500 ml in group 2, and the 
number of patients with consumption coagulopathy declined 
from 3 out of 33 to 2 out of 41 patients. Atrial fibrillation, 
considered a minor morbidity, was the most frequent 
complication (33%) but also the easiest to resolve. All cases 
except 1 which required electrical cardioversion, were 
successfully managed with pharmacological cardioversion. 
Another, less frequently encountered complication which 
occurs more often in the left hemithorax is intrathoracic 
herniation of abdominal contents. In the first part of our 
series this complication occurred twice, and in both cases 
required another thoracotomy to replace the viscera in the 
abdominal cavity. Since then we have used a simple 
procedure to prevent intrathoracic herniation: a second 
prosthesis is positioned and packed into the reconstruction 
defect between the vertebral bodies and the posterior costal 
arch (Figs. 3, 4). 
 The oncological follow-up of the 71 survivors, divided 
into two subgroups with 6 patients with biphasic MPM and 
65 patients with epithelial MPM, indicated that 14 out of 71 
patients survived at least 3 years. The details regarding 
survivors are below. 
 -2 patients are alive at >10 years: one had postoperative 
pleural empyema and is currently undergoing 
radiochemotherapy for retroperitoneal recurrence, the other 
was operated on for mesothelioma in situ and remained 
disease-free. 
 
Fig. (3). Left pleuro-pneumo-phreno-pericardiectomy without 
pericardioplasty and with posterolateral prosthetic packing to 
prevent intrathoracic herniation of abdominal contents. 
 
Fig. (4). CT scan of the same patient showing posterolateral 
prosthetic packing. 
 -2 patients are alive at >3 years. One is undergoing 
chemotherapy for resected retroperitoneal recurrence 
(identified as sarcomatoid MPM), after EPP and 
radiotherapy for epithelial MPM. 
 -2 patients died of peritoneal recurrence at 7 and 8 years 
respectively. 
 -8 patients survived 3 years. 
 In 36 cases (50.7%) it was possible to administer 
complete standard adjuvant radiotherapy to the hemithorax 
and retroperitoneum with an average dose of 50Gy and since 
2007 we have used helical tomotherapy. Fifteen (21%) of the 
71 survivors tolerated three additional cycles of 
Progress in Radical Surgery for Malignant Pleural Mesothelioma The Open Cardiovascular and Thoracic Surgery Journal, 2013, Volume 6   13 
chemotherapy to complete trimodal therapy (11 of the 39 in 
the second group). 
 The MIB-1 tumor indices were used to help determine 
prognosis. Patients whose tumors showed an interaction 
between monoclonal antibodies and the nuclear protein Ki 
67 were started on more intensive adjuvant therapy. 
 The impact of adjuvant radiotherapy on overall survival 
was investigated and statistically significant survival benefits 
(p=0.03) were observed within the first 40 months (30% 
versus 15%) (Fig. 5). The patients with the most favorable 
prognosis were those who received the fewest transfusions 
(20% survival at 5-7 years and 10% at 10 years in those with 
only two transfusions and death at 20 months in those given 
three to five transfusions; Fig. 6), those with MIB-1 positive 
cancer cells (20% versus 10% at 30 months with p=0.03), 
those who were diagnosed with stage I epithelial MPM (Fig. 
7), and those who received diaphragmatic prostheses (Fig. 
8). Differences in patients’ sex, age, preoperative talc 
poudrage, postoperative chemotherapy and SUV in the two 
groups were not statistically significant. 
Fig. (5). Follow-up of the 71 survived patients according to 
postoperative radiotherapy status. 
 
Fig. (6). Follow-up of the 71 survived patients according to blood 
loss. 
 
Fig. (7). Follow-up according to TNM stage in 66 survived 
epithelial mesothelioma. 
 
Fig. (8). Follow-up of the 71 survived patients according to 
diaphragmatic prostheses status. 
DISCUSSION 
 EPP appears to be the most effective form of therapy in 
the treatment of stage I and II malignant pleural epithelial 
mesothelioma [1]. Both intraoperative radiotherapy with 4-
15Gy (9), and palliative surgery (simple pleurectomy) alone 
[7] or associated with intrathoracic hyperthermic 
chemotherapy [2], photodynamic therapy [4], or 
immunotherapy [5], do not favor long term survival and in 
some cases have led to serious morbidity [2]. 
 Since the patients in our series did not easily tolerate 
trimodal therapy and only 15 out of 71 patients (21%), who 
were all in stage II, considered advanced disease, completed 
it. Another study (a multicenter phase II trial) of the same 
neoadjuvant chemotherapy (pemetrexed plus cisplatin) 
followed by EPP showed that initial clinical stage at the time 
of surgery was improved in 15.8%, unchanged for 42.1% 
and worsened in 28.1% [3]. 
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 EPP is a high risk procedure [2]. Increased risk is 
associated with cardiorespiratory function, length of 
operative time, extent of blood loss, and use of preoperative 
chemotherapy or intraoperative procedures such as 
thermotherapy. Undoubtedly the most important risk 
evaluation parameters are echocardiography, stress 
echocardiography, the predicted FEV1, the PCO2, PO2 and 
renal function values. In our experience lung perfusion 
values in the affected lung were especially important, with 
values <20% indicating high risk. We believe that a 
predicted FEV1 >1.3L can be associated with a favorable 
postoperative course and tolerance of trimodal therapy [8]. 
 In our series oncological indications for EPP were 
primarily based on staging both by thoracoscopy and CT 
scan, (3D CT scan in our last 15 patients to define more 
precisely the borders of the diaphragm, pericardium, ribs and 
aorta). Preoperative cytology of pleural liquid was positive 
in only 15% of cases and the indications for EPP were 
primarily based on clinical and diagnostic elements, 
especially on thoracoscopic evaluation and histopathology. 
In 4 patients, 2 from each group, the indications were 
provided by thoracotomy since 10 preoperative pleural 
biopsies were negative although there was strong 
radiological suspicion of MPM. After preoperative 
functional evaluation and adequate staging of these 4 
patients, we proceeded to perform an EPP when the 
intraoperative histopathology report identified 
epitheliomorphic MPM, and we resected four stage I tumors. 
The last 16 EPP procedures were preceded by talc 
pleurodesis, a technical decision based on the intraoperative 
observation that dissection was usually easier on the chest 
wall and diaphragm in patients who had undergone palliative 
talc pleurodesis in another institution, before transfer to our 
department. As a result the pleural cavities of our 16 patients 
were free of residual liquid and the chance of contamination 
of the pleural cavity was reduced to a minimum [9]. After 1 
year the patients’ condition has remained unchanged. SUV 
played an important role in patients of group 2. A low SUV 
(<4), indicating low metabolism, sometimes induced us to 
take into consideration borderline cases or even patients 
suffering from biphasic MPM [10]. Patients with this type of 
MPM, besides not being indicated for elective surgery, 
usually have an SUV >10 [7]. 
 In the literature, the PET scan is not recognized as having 
an important role in extrathoracic staging, rather than 
locoregional staging [11, 12]. However, the PET scans 
induced us to perform a thoracoscopy which enabled us to 
diagnose MPM in 2 of our patients who were otherwise 
indeterminate and without pleural effusion according to 
chest CT scan. 
 We also modified our surgical technique, using double 
unilateral thoracotomy instead of a classic thoracotomy by 
posterolateral incision along the 6
th
 rib. We performed 24 
double thoracotomies in the second part of our series, with a 
second, smaller incision along the 11
th
 rib, which we initially 
used only for the exeresis of large talc granulations and for 
pachypleuritic forms of mesothelioma [7]. This permitted 
optimal dissection of the costal insertions of the 
hemidiaphragm, control of the abdominal and retroperitoneal 
viscera, and most importantly, easy anchoring of the 
diaphragmatic prosthesis at the level of the 10
th
 rib, with 
interrupted sutures in a U shape. 
 A second thoracotomy along the 8
th
 rib, as suggested by 
other authors [7], seemed too cranial and likely to cause 
difficulties in anchoring the prosthesis caudally on the chest 
wall, keeping the cardiac axis raised and inclined with 
respect to the root of the aorta. 
 In the median sternotomy approach sometimes used in 
EPP, the exeresis of the posterior diaphragmatic insertions 
and anchoring of the prosthesis are technically complex. It 
does not seem attributable purely to chance that, as reported 
in the literature, some patients undergo as many as 7 
additional thoracotomies after this procedure [13,14]. 
 Evolving surgical experience induced us to omit 
pericardial prostheses in the last 10 left EPP procedures, as 
suggested by some authors [8], because in 2 cases this type 
of prosthesis caused adhesive pericarditis and a severe 
pumping defect of the right heart which obliged us to 
perform another thoracotomy. Leaving the heart free in the 
chest cavity and lowering the diaphragmatic prosthesis by 
anchoring it to the 10
th
 rib did not cause hemodynamic 
problems except for a higher incidence of atrial fibrillation, 
(40% in the first group versus 33% of the second group), and 
in 2 cases the appearance of a right pleural effusion of about 
700ml which had to be drained after CT scan showed 
infiltration of the anterior mediastinum. 
 An additional technical improvement in EPP is the 
application of thrombin to the decorticated chest wall and the 
bleeding areas of the mediastinum. Topical application of 
thrombin has been shown to be especially effective in 
patients without coagulation defects and without significant 
intraoperative blood loss [15]. Postoperative blood loss, 
which was controlled in the usual way with both thoracic and 
subdiaphragmatic drains, was significantly reduced in our 
patients, (from 900-1400ml to 300-500ml in the first 24 
hours), and as a result perioperative morbidity also declined 
(from 27.2% to 14.6%). The use of thrombin did not prevent 
2 cases of hemothorax due to consumption coagulopathy in 
patients who had been given multiple transfusions and had a 
past medical history of non-steroidal anti-inflammatory drug 
(NSAID) abuse. We do not yet have sufficiently definitive 
data to determine whether limiting transfusions affects 
follow-up positively, but follow-up data on 5 of our patients 
who were reoperated for consumptive coagulopathy and who 
survived <6 months, points in this direction. 
 Our series will permit us to evaluate patients at follow-up 
to determine the prognostic efficacy of various survival 
factors such as those having had a low number of 
transfusions. Follow-up at 24 months shows that 51.8% of 
our patients were free of disease after trimodal therapy, 
including a positive MIB-1 index [16], those with helical 
tomotherapy [17, 18], stage I tumor, presence of 
epitheliomorphic cells, the use of prostheses, and double 
unilateral thoracotomy. 
CONCLUSIONS 
 In recent years the role of radical surgery in the treatment 
of MPM has become progressively more important because 
of improved indications, fewer complications, and better 
long term results. 3D-CT scan of the pericardium, diaphragm 
Progress in Radical Surgery for Malignant Pleural Mesothelioma The Open Cardiovascular and Thoracic Surgery Journal, 2013, Volume 6   15 
and chest wall and FDG PET scan of the chest and abdomen, 
provide significant improvement in clinical imaging. 
Preoperative talc pleurodesis facilitates extrapleural 
dissection although this did not improve follow-up in our 
experience. The use of diaphragmatic prostheses permits 
more radical surgery. Double unilateral thoracotomy has 
made it possible to control the costophrenic space and 
correctly anchor the diaphragmatic prosthesis which remains 
well attached caudally without compressing the heart on the 
left. Topical application of thrombin results in less 
postoperative bleeding. 
 The innovations described above, especially the new 
reconstruction procedures, have reduced patient morbidity. 
Adjuvant radiotherapy and especially helical tomotherapy 
[18] have improved the follow-up for patients with epithelial 
MPM, (although unfortunately only 11 out of 39 patients 
(28%) in group 2 were able to tolerate trimodality therapy) 
[1]. To further improve the understanding of long-term 
results after radical surgery for MPM, we believe that based 
on our experiences to date and the currently available data, 
that it is not premature to add the following new clinical 
factor the MIB-1 index, to the well-known prognostic factors 
for MPM (stage I TNM classification, presence of 
epitheliomorphic cells, and adjuvant therapy). This indicates 
the utility of screening asbestos workers since only patients 
with MPM at stage 1 TNM have a favorable follow-up and, 
for this purpose, we have found that the FDG-PET scan is 
currently the most specific and practical clinical procedure. 
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